Glaukos Corporation
GKOSStock
$155.39+59.62%52W
Market Cap$9.22B
P/E—
Div yield—
Beta0.76
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)28.45%
Price vs S&P 500 (4W)22.39%
VGM Score57.15
Market Capitalization$9.22B
Earnings Surprise History
Q1 26-0.18est. -0.28
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.18
4.18
4.24
4.24
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GKOSGlaukos Corporation | F | A | A | $155.39 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
Glaukos develops innovative ophthalmic therapies and devices for treating glaucoma, corneal disorders, and retinal diseases. The company commercializes the iStent family of micro-scale glaucoma surgical devices and the novel iDose TR intracameral implant, which delivers continuous glaucoma medication directly inside the eye as an alternative to daily eye drops. It also offers treatment for keratoconus, a rare corneal condition.